Transcenta Holding Limited (HKG:6628)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
The Discovering, Developing, Manufacturing and Commercializing Novel Drugs	7.44M	11.26M	53.85M	101.89M	50.24M
The Discovering, Developing, Manufacturing and Commercializing Novel Drugs Growth	-33.98%	-79.09%	-47.15%	102.80%	-37.96%
Total	7.44M	11.26M	53.85M	101.89M	50.24M
Total Growth	-33.98%	-79.09%	-47.15%	102.80%	-37.96%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Chinese Mainland	6.63M	10.14M	-	-	-
Chinese Mainland Growth	-34.63%	-	-	-	-
United States of America	808.00K	970.00K	-	-	-
United States of America Growth	-16.70%	-	-	-	-
Others	-	153.00K	-	-	-
PRC	-	-	53.85M	101.89M	50.24M
PRC Growth	-	-	-47.15%	102.80%	-37.96%
Total	7.44M	11.26M	53.85M	101.89M	50.24M
Total Growth	-33.98%	-79.09%	-47.15%	102.80%	-37.96%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 6, 2026

Data Sources Report a data error